Beyond automation: Redesigning pharmacovigilance for the age of AI
Pharmacovigilance (PV) has reached an inflection point. We face accelerating data growth, expanding regulatory requirements, and rising expectations for proactive safety surveillance, which means that transformation through incremental change is no longer enough. Instead, we need to redesign our approach to this critical work, and AI is essential to our strategy.
Over the next three years, the safety organizations that realize the greatest benefits from AI will be those that prioritize not automation of individual tasks but the deliberate orchestration of human and machine intelligence. In this model, AI moves beyond rule-based automation to manage information flows, execute transactional work, and surface exception-based insights, enabling safety scientists to focus on uncertainty, interpretation, and risk-based decision-making. AI continually learns from their judgments, as well as from new data and patterns, resulting in better context. This supports the formation of deeper human insights and creates a living repository of institutional knowledge, ultimately resulting in better safety decisions and patient outcomes.
With this new approach:
- Quality control involves ongoing learning, not simply error detection.
- Aggregate reporting enables deeper, more proactive evaluation of emerging safety trends and benefit-risk profiles.
- Signal detection noise is reduced by prioritizing the most relevant potential signals for scientific review, allowing experts to focus on meaningful safety questions rather than high-volume screening.
Today's AI implementations are early manifestations of this future state — one that will require us to address a fundamental mismatch between how PV processes are designed and how safety professionals create value. PV platforms depend on structured, standardized data. The activities that ultimately drive patient safety decisions, however — including causality assessment, signal evaluation, and benefit-risk analysis rely on clinical judgment, contextual reasoning, and the ability to navigate ambiguity. Asking users to move continuously between these modes of work introduces unnecessary opportunities for error.
Within the next two to three years, advances in agentic AI architectures and operational intelligence layers will allow organizations to separate these modes more cleanly, with AI handling information-system demands and routing knowledge work to the human experts equipped to perform it. Realizing these benefits, however, will require a high degree of AI readiness, including the operational expertise, governance, process design, data foundations, and workforce capabilities needed to effectively deploy, scale, and continuously improve AI-enabled workflows. This will require a shift away from the task-oriented model that has long defined PV operations and toward a human-centered, intelligence-driven approach that prioritizes quality interpretation and scientific analysis. The foundations for this change are already in place. In this paper, we describe the design principles and working implementations that make this model practical.
Ensuring traceability and explainability
Quality assurance in PV — the framework for ensuring the accuracy of safety-related deliverables — largely focuses on detecting and addressing compliance issues after potential problems occur. In the past, improving quality usually meant improving quality control mechanisms. But with AI, we are implementing a new model in which corrections are continuously fed back into the system to progressively improve output.
Every interaction becomes an opportunity to capture and capitalize on organizational knowledge. Over time, the result is a structured feedback loop in which AI performance is continuously refined by the judgment of the people reviewing it.
For traceability and explainability, however, such workflows must maintain a clear record of the decision-making path. Consider a common scenario: a foreign-language individual case safety report (ICSR). First, AI translates the source document, extracts reportable entities, maps them to structured fields, and runs a duplicate check against the safety database. Then an expert reviews. All reviewer-initiated corrections help establish a baseline for improving future accuracy. At Parexel, this feedback process operates entirely in the backend so the reviewer's process remains unchanged.
This approach provides traceability because every correction is logged with context. It also creates explainability over time. As corrections accumulate, change control analysis can identify systematic patterns, such as extraction types that consistently require human adjustment or data sources that cause model performance to drift. Together, these form a documented human-in-the-lead governance framework that reinforces responsible product stewardship, maintains accountability for safety decisions, and provides a transparent record of how expert judgment shapes AI-enabled workflows.
Aggregate reporting drives deeper, evaluation of emerging safety trends
Historically, report aggregation has been one of the most labor-intensive aspects of pharmacovigilance. AI can accelerate reporting by organizing underlying safety data and generating draft content for narrative sections, statistical summaries, and line listings. More importantly, AI enables users to assemble draft reports continuously so they can identify significant signals well before lock points and submission deadlines. As a result, aggregate reporting becomes an ongoing intelligence function rather than an intermittent compliance obligation.
In the traditional model, data accumulates until a reporting period closes, at which point safety professionals analyze the data and document their findings. Reports are useful but staggered. In the emerging AI-supported model, however, reports are the byproduct of an ongoing intelligence process rather than the process’s primary objective. This approach allows experts to make continuous use of data that is synthesized in real time so they can interrogate emerging patterns and take informed action.
Because AI-generated reports can appear polished and complete even when inferences are not fully supported by the underlying data, expert review is critically important. That review must operate at scale, across multiple products and reporting cycles.
We recommend a workflow in which reviewers collaborate concurrently rather than sequentially. Instead of a handoff from a safety scientist to physician to medical writer, for example, all three roles review and refine AI-generated content in parallel, with visibility into each other's contributions. The system should also track report history across versions so review assignments can be calibrated automatically: a routine update of an established product may require standard scientific review, while a first-cycle report for a newly approved therapy with emerging safety signals would be routed to senior medical and scientific experts.
At Parexel, we operationalize this approach through collaborative tools that log all user modifications, annotations, and rationale alongside the AI-generated draft. The result is a complete audit trail in which every human judgment and AI contribution can be traced to its source.
Report aggregation
An agentic approach to signal management
As with aggregate reporting, AI can make signal management a source of ongoing intelligence. Most important, it can help separate meaningful signals from noise, addressing one of the most persistent challenges in pharmacovigilance. In traditional signal detection, a single statistical method is applied at fixed intervals and a safety scientist must manually query the safety database and pull case narratives before analyzing the evidence and reporting on it.
In the emerging model of signal management, AI can run multiple detection methods in parallel on the same dataset: disproportionality analyses, clinical pattern recognition across case narratives, and literature-informed signal enrichment. The investigation is orchestrated by the safety scientist, who uses their expertise to:
- Frame the most useful research questions
- Recognize relevant patterns
- Understand limitations and biases and challenge AI outputs accordingly
- Determine additional evidentiary needs
- Synthesize contradictory evidence
- Bring the investigation to a reasoned and supportable conclusion
AI elevates a user’s signal management capabilities. But to be used to its fullest advantage, AI also requires significant user expertise.
In an agentic workflow, AI agents can be directed to execute various queries and searches in parallel. Each agent operates within its defined scope as the safety scientist directs the overall investigation, which might include adjusting search parameters, requesting deeper analysis on a specific patient subgroup, or redirecting an agent toward a data source it missed. AI accelerates the mechanical work while the scientist uses clinical reasoning to determine the meaning of the findings. Every user decision is logged with context.
This workflow also enables real-time multidisciplinary input. When the investigation requires medical judgment or biostatistical validation, the system routes the relevant findings and draft content to the appropriate expert for review — an in-progress consultation rather than a downstream handoff. The physician or biostatistician has full visibility into the AI-generated evidence and the scientist's annotations and decision path.
The cumulative effect is that signal management becomes a continuous analytical function in which each evaluation builds on institutional knowledge captured in prior investigations.
Agentic signal management
Empowering experts and expanding collaboration
It’s easy to assume that routine-task automation will naturally result in more deep-expertise work from safety staff. But what AI amplifies depends on how organizations measure its value. When the value of AI-assisted work is assessed based on volume — cases processed, fields populated, reports generated — people predictably use AI to do more of what they were already doing. In these situations, throughput increases.
But if quality is an organization’s standard of measurement, experts generally redirect their time toward the interpretive work that determines patient safety outcomes. This means that upskilling alone is insufficient. Organizations must also deliberately shift operational metrics to focus on quality. The metric shift must come first; training people to use AI effectively within a volume-based incentive structure will produce faster volume, not better outcomes.
To ensure quality improvement, every human and AI action in a workflow must be documented. When a safety scientist corrects an AI-generated causality assessment and documents the reasoning, that annotation becomes part of the institutional record. When a physician reviewer adds clinical context to a signal evaluation, that context is preserved alongside the data it interprets. Over time, this accumulated body of reasoning provides a training signal that improves AI performance. It also creates a searchable knowledge base for human users.
Collaboration then becomes a mechanism for expertise development: junior safety professionals learn from the reasoning of senior colleagues, and AI agents reference this context so that their outputs are grounded in the organization's own analytical history.
Equally important, the benefits of AI do not arise from technology alone. They depend on organizational AI readiness: the ability to translate technical capabilities into sustainable operational value. This requires significant upfront work to define business requirements, redesign workflows, establish governance frameworks, conduct rigorous validation and user acceptance testing, and implement mechanisms to monitor performance, compliance, and business outcomes. Success therefore depends on a collective effort across safety, quality, regulatory, operational, and technology dimensions. Organizations that treat AI as a technology deployment may achieve automation; organizations that treat it as an operational transformation are more likely to achieve better safety decisions, greater efficiency, and lasting value.
The emerging PV model: Putting human expertise at the center
The approach we’ve described represents a structural change in how PV organizations define the relationship between AI systems and human expertise. AI handles the volume: extracting, structuring, coding, drafting, and detecting patterns across datasets at a speed that no manual process could match. Meanwhile, human experts handle the interpretation: assessing causality, evaluating clinical significance, and making the decisions that ultimately protect patients.
This emerging model also prioritizes continuous learning so that PV becomes an ongoing analytical function rather than a periodic sequence of processing and reporting cycles. And this continuous-learning approach transforms PV into a source of institutional knowledge as expert decisions are captured and fed back into safety systems.
Multiple aspects of this approach exist today: AI-assisted case intake with structured feedback loops, collaborative aggregate report development, and multi-method signal detection. Others, including fully agentic workflows in which AI modules operate under expert orchestration, are in advanced development. On the horizon, the integration of real-world data sources into signal detection will extend this model further, a topic we will address in a subsequent publication.
All of this work rests on a consistent design principle: that AI systems in PV exist to facilitate and extend[AB8.1] human expertise. The success of these systems should be measured by the quality of resulting safety decisions, the speed at which meaningful signals reach the right experts, and the rigor of the evidence trail supporting every conclusion. These are the standards of a model that is faster, more thorough, and more intelligent than what either humans or AI could deliver independently. The foundations of this model are already emerging today. The leaders of tomorrow will be the organizations that start building the operational, scientific, and governance capabilities needed to realize its full potential now.
Related Insights
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
Blog
Human-centered AI - A dual-layer model for clinical research excellence
Jul 1, 2026
Blog
The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem
Jul 1, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Whitepaper
AI-powered pharmacovigilance: From reactive reporting to predictive risk
Mar 24, 2025
Podcast
Enabling Successful Sites: Episode 4, Part Two: Leveraging AI to improve patient recruitment and retention
Jan 6, 2025
Whitepaper
Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Nov 25, 2024
Article
Human-in-the loop AI: a proven approach to streamlining PV case processing and review
Oct 7, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024
Related Insights
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
Blog
Human-centered AI - A dual-layer model for clinical research excellence
Jul 1, 2026
Blog
The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem
Jul 1, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Whitepaper
AI-powered pharmacovigilance: From reactive reporting to predictive risk
Mar 24, 2025
Podcast
Enabling Successful Sites: Episode 4, Part Two: Leveraging AI to improve patient recruitment and retention
Jan 6, 2025
Whitepaper
Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Nov 25, 2024
Article
Human-in-the loop AI: a proven approach to streamlining PV case processing and review
Oct 7, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024

